In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
- Pathogens. 2015 Aug 18;4(3):620-5. doi: 10.3390/pathogens4030620.
Affiliations
- 1. Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA. [email protected].
- 2. Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA. [email protected].
- 3. Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102, USA. [email protected].
PMID: 26295262
DOI: 10.3390/pathogens4030620
Abstract
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to ≥3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms.
Keywords
ESBL; Escherichia coli; Klebsiella pneumonia; carbapenemase; β-lactamase inhibitor.
Products